J Nucl Med. 2026 Jan 2;67(1):4-11. doi: 10.2967/jnumed.125.270889. ABSTRACT Continuation of effective and well-tolerated systemic treatment is often performed in care for metastatic castration-resistant prostate cancer. Likewise, continued administration of Lu-PSMA radiopharmaceutical therapy beyond the approved number of cycles holds…
